13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
36 檔
32.9%
According to the latest 13F quarterly dataset, Sector Gamma As managed an equity portfolio of $461.0M at the end of Q4 2025, spanning 36 distinct U.S. exchange-listed positions.
Sector Gamma As executed strategic sector rebalancing during Q4 2025, establishing 3 new positions while fully exiting 8 holdings and trimming 10 positions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, MRK, MDT) accounted for 32.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
REGN
市值: $5.5M
Top Position Liquidated / Trimmed
BAX
前期市值: $8.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 9.17% | -2.78% | +28.33% | |
| 2 | MRK | Merck & Co. Inc. | Stock-Healthcare | 8.73% | -1.34% | +12.76% | |
| 3 | MDT | Medtronic plc | Stock-Healthcare | 5.90% | +0.24% | -11.14% | |
| 4 | BDX | Becton Dickinson And Co | Stock-Healthcare | 5.86% | -0.01% | +21.64% | |
| 5 | GILD | Gilead Sciences Inc | Stock-Healthcare | 4.94% | -1.75% | EXIT | |
| 6 | INCY | Incyte CORP | Stock-Healthcare | 4.93% | -0.26% | +6.66% | |
| 7 | PFE | Pfizer Inc | Stock-Healthcare | 4.88% | -1.99% | -31.35% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 4.55% | -1.86% | -0.81% | |
| 9 | BIIB | Biogen Inc | Stock-Healthcare | 3.43% | -1.36% | +13.25% | |
| 10 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.34% | +0.26% | -31.73% | |
| 11 | CVS | Cvs Health CORP | Stock-Healthcare | 3.21% | +1.19% | +13.70% | |
| 12 | CAH | Cardinal Health Inc | Stock-Healthcare | 2.90% | -0.64% | +4.05% | |
| 13 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.86% | +3.65% | NEW | |
| 14 | BRKR | Bruker CORP | Stock-Healthcare | 2.73% | -0.18% | +1.51% | |
| 15 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 2.72% | -0.67% | +16.74% | |
| 16 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.69% | +0.46% | +12.88% | |
| 17 | ELV | Elevance Health Inc | Stock-Healthcare | 2.60% | +0.69% | +238.91% | |
| 18 | CNC | Centene CORP | Stock-Healthcare | 2.42% | +1.00% | +21.06% | |
| 19 | GEHC | GE Healthcare Technology | Stock-Healthcare | 2.14% | +0.77% | +2.69% | |
| 20 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.87% | +0.05% | +32.09% | |
| 21 | AVTR | Avantor Inc | Stock-Healthcare | 1.82% | +0.66% | +45.76% | |
| 22 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.64% | +0.56% | +4.04% | |
| 23 | LH | Labcorp Holdings Inc | Stock-Healthcare | 1.55% | +0.38% | +4.04% | |
| 24 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.42% | -1.67% | EXIT | |
| 25 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.34% | -0.34% | -0.91% | |
| 26 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.26% | +2.13% | NEW | |
| 27 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.22% | +0.12% | — | |
| 28 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.21% | -0.43% | +19.57% | |
| 29 | DXCM | Dexcom Inc | Stock-Healthcare | 1.15% | +0.66% | -0.91% | |
| 30 | HCA | Hca Healthcare Inc | Stock-Healthcare | 1.15% | — | -0.91% | |
| 31 | KURA | Kura Oncology Inc | Stock-Other | 1.08% | +0.24% | +3.97% | |
| 32 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.07% | +0.56% | -47.57% | |
| 33 | ASND | Ascendis Pharma A/S | Stock-Other | 0.79% | -1.15% | EXIT | |
| 34 | CGON | Cg Oncology Inc | Stock-Other | 0.49% | — | — | |
| 35 | OGN | Organon & Co | Stock-Healthcare | 0.49% | +0.27% | -44.82% | |
| 36 | CERT | Certara Inc | Stock-Other | 0.46% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | +2.7% | +28.33% | Add |
| 2 | MRK | Merck & Co. Inc. | +2% | +12.76% | Add |
| 3 | ELV | Elevance Health Inc | +1.8% | +238.91% | Add |
| 4 | GILD | Gilead Sciences Inc | +0.9% | +19.81% | Add |
| 5 | BDX | Becton Dickinson And Co | +0.8% | +21.64% | Add |
| 6 | BIIB | Biogen Inc | +0.8% | +13.25% | Add |
| 7 | BRKR | Bruker CORP | +0.7% | +1.51% | Add |
| 8 | TMO | Thermo Fisher Scientific Inc | +0.6% | +17.59% | Add |
| 9 | INCY | Incyte CORP | +0.6% | +6.66% | Add |
| 10 | LNTH | Lantheus Holdings Inc | +0.6% | +45.68% | Add |
| 11 | CAH | Cardinal Health Inc | +0.6% | +4.05% | Add |
| 12 | CNC | Centene CORP | +0.5% | +21.06% | Add |
| 13 | TNDM | Tandem Diabetes Care Inc | +0.5% | -0.91% | Trim |
| 14 | EW | Edwards Lifesciences CORP | +0.5% | +32.09% | Add |
| 15 | SNDX | Syndax Pharmaceuticals Inc | +0.4% | +19.57% | Add |
| 16 | AVTR | Avantor Inc | +0.3% | +45.76% | Add |
| 17 | BMRN | Biomarin Pharmaceutical Inc | +0.3% | +12.88% | Add |
| 18 | CVS | Cvs Health CORP | +0.3% | +13.70% | Add |
| 19 | AMGN | Amgen Inc | +0.3% | -0.81% | Trim |
| 20 | KURA | Kura Oncology Inc | +0.1% | +3.97% | Add |
| 21 | GEHC | GE Healthcare Technology | +0.1% | +2.69% | Add |
| 22 | BIO | Bio-rad Laboratories-a | +0.1% | +4.04% | Add |
| 23 | HCA | Hca Healthcare Inc | — | -0.91% | Trim |
| 24 | ZBH | Zimmer Biomet Holdings Inc | -0.1% | +16.74% | Add |
| 25 | DXCM | Dexcom Inc | -0.1% | -0.91% | Trim |
| 26 | CERT | Certara Inc | -0.2% | — | Unchanged |
| 27 | LH | Labcorp Holdings Inc | -0.3% | +4.04% | Add |
| 28 | ASND | Ascendis Pharma A/S | -0.4% | -32.98% | Trim |
| 29 | PTCT | Ptc Therapeutics Inc | -0.7% | -47.57% | Trim |
| 30 | OGN | Organon & Co | -1% | -44.82% | Trim |
| 31 | IONS | Ionis Pharmaceuticals Inc | -1.1% | -31.73% | Trim |
| 32 | MDT | Medtronic plc | -1.3% | -11.14% | Trim |
| 33 | PFE | Pfizer Inc | -3% | -31.35% | Trim |
| 34 | BAX | Baxter International Inc | — | EXIT | Sold out |
| 35 | VTRS | Viatris Inc | — | EXIT | Sold out |
| 36 | HUM | Humana Inc | — | EXIT | Sold out |
| 37 | ELAN | Elanco Animal Health Inc | — | EXIT | Sold out |
| 38 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| 39 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 40 | ICLR | ICON Public Limited Company | — | EXIT | Sold out |
| 41 | SOLV | Solventum CORP | — | EXIT | Sold out |
| 42 | BNTX | Biontech Se-adr | — | EXIT | Sold out |
| 43 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 44 | CGON | Cg Oncology Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 36 disclosed positions in Q4 2025.
During Q4 2025, Sector Gamma As's top holdings by market value included BMY (9.2%)、MRK (8.7%)、MDT (5.9%). The largest single position, BMY, represented 9.2% of total portfolio value.
In Q4 2025, Sector Gamma As made 43 total portfolio adjustments, initiating 3 new buys, adding to 22 positions, trimming 10 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.